Sputnik V needs to be priced at par with Covishield & Covaxin
Market penetration of Sputnik V will depend on competitive pricing, government orders and the ability to meet soaring demand through timely supply
Market penetration of Sputnik V will depend on competitive pricing, government orders and the ability to meet soaring demand through timely supply
Essential medicines were made available to more than 150 countries around the world during the pandemic
The current production capacity of indigenously developed Covaxin vaccine will be doubled by May-June 2021 and then increased nearly 6-7 fold by July-August 2021.
Both the vaccines have been extensively tested by IVRI for safety and potency and have been found to provide 100% protection
The government has taken all the effective measures to make healthcare affordable
ICICI Securities expects Hemmo to grow its revenue at a CAGR of 30.0% over FY21E-FY23E
GSKP announced sale of its newly constructed manufacturing plant at Vemgal, Karnataka to Hetero Labs for a cash consideration of Rs1.8bn
Report outlines the wide array of investment opportunities in various segments of India’s healthcare sector
Has signed a 12-year, off-site, virtual power purchase agreement (VPPA) with Enel Green Power
174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.
Subscribe To Our Newsletter & Stay Updated